Listing of Claims:

Claim 1 (currently amended) A compound selected from the group consisting of a compound of the formula I

$$(B)_{s}$$

$$(B)_{t}$$

$$(B)_{t}$$

$$V$$

$$N = N$$

in which G is a residue of the formula H

$$\hbox{-(}CR^1R^2)_n\hbox{-}A\hbox{-(}CR^1R^2)_m\hbox{-(}CR^1R^3)_i\hbox{-(}CR^1R^2)_q\hbox{-}R^4 \\ \qquad \hbox{ } H$$

A is selected from the group consisting of a direct bond,

-S(O)₂-, (C₂-C₄)-alkynediyl, (C₂-C₄)-alkenediyl, and (C₅-C₁₄)-arylene where in the arylene residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms a heteroatom selected from the series group consisting of nitrogen, oxygen and sulfur, or a divalent residue of a 3-membered to 7-membered saturated or unsaturated ring which can contain one or two ring heteroatoms selected from the series group consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by residues from the series a member selected from the group

consisting of =O, =S and R³;

B is are individually selected from the group consisting of (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylsulfonyl-, aminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or and (C₅-C₁₄)-heteroaryl, where all residues B are independent of one another and can be identical or different;

X is selected from the group consisting of hydrogen, NR^6R^6 , fluorine, chlorine, bromine, $-OR^6$, $-SR^6$, hydroxy- (C_1-C_6) -alkyl-NH-, (hydroxy- (C_1-C_6) -alkyl)₂N-, amino- (C_1-C_6) -alkyl-NH-, (amino- (C_1-C_6) -alkyl)₂N-, hydroxy- (C_1-C_6) -alkyl-O-, hydroxy- (C_1-C_6) -alkyl-S- or and -NH-C(O)-R⁶);

Y is <u>selected from the group consisting of</u> R⁶, fluorine, chlorine, bromine, cyano, -NR⁶R⁶'-, <u>-</u>OR⁶, -SR⁶ or <u>and</u> hydroxy-(C₁-C₆)-alkyl-NH-;

Z is N or
$$\underline{CH}$$
;

R¹ and R² are <u>individually selected from the group consisting of</u> hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl,

 C_{14})-aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl, (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl-, R^6 -O- R^7 , R^6 -OS(O)_p- R^7 , R^6 S(O)₂NH R^7 , R^6 OC(O)NH R^7 or and R^6 R 6 N- R^7 , where all residues R^4 and R^2 are independent of one another and can be identical or different;

R³ is selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₈)-alkyl, (C₂) to C₁₈)-alkenyl, (C₂ to C₁₈)-alkenyl (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶R⁶'N-R⁷, R⁶C(O)-O-R⁷, R⁶C(O)R⁷, R⁶OC(O)R⁷), (R⁶N(R⁶)C(O)OR⁷, R⁶S(O)_pN(R⁵)R⁷, R⁶S(O)_pN(R⁵)R⁷, R⁶C(O)N(R⁵)R⁷, R⁶N(R⁶)C(O)N(R⁵)R⁷, R⁶N(R⁶)S(O)_pR⁷, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by a member selected from the group consisting of R⁶, fluorine, chlorine, bromine, cyano, trifluoromethyl, R⁶R⁶NR⁷, nitro, R⁶OC(O)R⁷, R⁶C(O)R⁷, R⁶N(R⁶)C(O)R⁷, R⁶N(R⁶)S(O)_pR⁷ or and R⁶-O-R⁷, and where all R³s are independent of one another and can be identical or different;

R⁴ is selected from the group consisting of -C(O)R⁸, -C(S)R⁸, -S(O)_pR⁸, -S(O)_pR⁸, -P(O)R⁸R^{8'} or a residue of and a 4-membered to 8-membered saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms selected from the series group consisting of nitrogen, oxygen and sulfur;

 R^5 is selected from the group consisting of hydrogen, (C_1-C_{10}) -alkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) aryl or and (C_5-C_{14}) aryl- (C_1-C_8) -alkyl-, where all residues R^5 -are independent of one another and can be identical or different;

R⁶ and R⁶ are <u>individually selected from the group consisting of hydrogen</u>, (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-aryl, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl-(C

 R^7 is (C_1-C_4) -alkanediyl or a direct bond, where all residues R^7 are independent of one another and can be identical or different;

 R^8 and R^8 are individually selected from the group consisting of hydroxy, (C_1-C_8) -alkoxy, (C_5-C_{14}) -aryl- (C_1-C_8) -alkoxy-, (C_5-C_{14}) -aryloxy, (C_1-C_8) -alkylcarbonyloxy- (C_1-C_4) -alkoxy-, (C_5-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyloxy- (C_1-C_8) -alkoxy-, (C_5-C_{14}) -aryl-aryl-aryl-aryl- (C_1-C_8) -alkyl)amino)carbonylmethyloxy-, (C_5-C_{14}) -arylamino-, the residue of an amino acid, N- $((C_1-C_4)$ -alkyl)piperidin-4-yloxy-, 2-methylsulfonylethoxy-, 1,3-thiazol-2-ylmethyloxy-, 3-pyridylmethyloxy-, 2- $(di-((C_1-C_4)$ -alkyl)amino)-ethoxy or and the residue $Q^ (C_1-C_3)$ -alkyl-aryl-arylamino- in which Q^- is a physiologically tolerable anion, where all residues R^8 -and R^8 -are independent of one another and can be identical or different;

n is zero, one, two, three, four or five;

m is zero, one, two, three, four or five;

i is zero or one;

q is zero, one or two;

r is zero, one or two;

s is zero, one, two or three;

t is zero, one, two, three, four, five, six, seven or eight;

p is zero, one or two, where all numbers p are independent of one another and can be identical or different;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their <u>non-toxic</u>, physiologically tolerable salts and their prodrugs;

where, instead of the purine structure shown in formula I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present.

Claim 2 (currently amended) A compound of the formula I as claimed in claim 1, in which wherein G is a residue of the formula II

$$-(CR^{1}R^{2})_{n}-A-(CR^{1}R^{2})_{m}-(CR^{1}-R^{3})_{i}-(CR^{1}R^{3})_{i}-(CR^{1}R^{2})_{q}-R^{4}$$
 #

A is selected from the group consisting of a direct bond,

-C(O)NR⁵-, -NR⁵C(O)-, -C(O)-, -NR⁵-, -O-, -S-, -S(O)-, -S(O)₂-, (C₂-C₄)-alkynediyl, (C₂-C₄)-alkenediyl, (C₅-C₁₄)-arylene where in the arylene residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms a heteroatom selected from the series group consisting of nitrogen, oxygen and sulfur, or and a divalent residue of a 3-membered to 7-membered saturated or

unsaturated ring which can contain one or two ring heteroatoms <u>selected</u> from the <u>series</u> group consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by <u>residues</u> a <u>member selected</u> from the <u>series</u> group consisting of =0, =S and R³;

B is selected from the group consisting of (C_1-C_{12}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl, (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoro-methyl, nitro, hydroxycarbonyl-, (C_1-C_6) -alkoxy, (C_1-C_6) -alkoxy- (C_1-C_6) -alkyl-, (C_1-C_6) -alkylcarbonyl-, (C_5-C_{14}) -arylcarbonyl-, (C_5-C_{14}) -aryl- (C_1-C_8) -alkylcarbonyl- (C_1-C_6) -alkylaminocarbonyl-, (C_1-C_6) -alkylsulfonylamino-, (C_1-C_6) -alkylsulfonylamino-, (C_1-C_6) -alkylsulfonyl-, (C_5-C_{14}) -arylsulfonyl-, (C_5-C_{14}) -aryl- (C_1-C_8) -alkylsulfonyl-, (C_5-C_{14}) -aryl- (C_1-C_8) -alkylsulfonyl-, (C_5-C_{14}) -aryl or and (C_5-C_{14}) -heteroaryl, where all residues Bs are independent of one another and can be identical or different;

X is selected from the group consisting of hydrogen, NH₂, -NH-C(O)-R⁶ of and OH;

Y is hydrogen;

Z is N;

 R^1 and R^2 are independently of one another are selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, (C_1-C_{10}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl, (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_1) -aryl- (C_1-C_8) -alkyl-, (C_5-C_1) -aryl- (C_1-C_8) -alkyl-, (C_5-C_1) -aryl- (C_1-C_8) -alkyl-, (C_5-C_1) -aryl- (C_1-C_8) -aryl-

R³ is selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, (C₁-C₁₈)-alkyl, (C₂-C₁₈)-alkenyl, (C₂-C₁₈)-alkynyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, R⁶-O-R⁷, R⁶R⁶'N-R⁷, R⁶C(O)-O-R⁷, R⁶C(O)R⁷, R⁶,N(R⁶)C(O)OR⁷, R⁶,S(O)_pN(R⁵)R⁷, R⁶SC(O)N(R⁵)R⁷, R⁶C(O)N(R⁵)R⁷, R⁶N(R⁶)C(O)N(R⁵)R⁷, R⁶N(R⁶)S(O)_pR⁷, where alkyl-can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl and heteroaryl can be monosubstituted or polysubstituted by a member selected from the group consisting of R⁶, fluorine, chlorine, bromine, cyano, trifluoromethyl, R⁶R⁶'NR⁷, nitro, R⁶OC(O)R⁷, R⁶C(O)R⁷, R⁶N(R⁶)C(O)R⁷, R⁶N(R⁶)S(O)_pR⁷ of and R⁶-O-R⁷, and where all residues R³ are independent of one another and can be identical or different;

 R^4 is $-C(O)R^8$ or $-P(O)R^8R^{8'}$;

 R^5 is selected from the group consisting of hydrogen, (C_1-C_{10}) -alkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl- or and $(C_5-C_{14}$ -aryl- (C_1-C_8) -alkyl-, where all residues R^5 are independent of one another and can be identical or different;

 R^6 and R^6 are individually selected from the group consisting of hydrogen, (C_1-C_{12}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl or and (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different individual substituents selected from the series group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C_1-C_6) -alkyl, (C_1-C_6) -alkoxy-, (C_1-C_6) -alkoxy- (C_1-C_6) -alkoxy- (C_1-C_6) -alkoxy- (C_1-C_6) -alkyl,

 (C_5-C_{14}) -arylcarbonyl-, (C_5-C_{14}) -aryl- (C_1-C_6) -alkylcarbonyl-, (C_1-C_6) -alkanoylamino-, (C_5-C_{14}) -arylsulfonylamino-, (C_1-C_6) -alkylsulfonylamino-, (C_1-C_6) -alkylsulfonyl-, (C_5-C_{14}) -aryl and (C_5-C_{14}) -heteroaryl, and where all residues R_6 and $R_{6'}$ are independent of one another and can be identical or different;

 R^7 is (C_1-C_4) -alkanediyl or a direct bond, where all residues R^7 are independent of one another and can be identical or different;

 R^8 and $R^{8'}$ are individually selected from the group consisting of (C_1-C_8) -alkoxy, (C_5-C_{14}) -aryl- (C_1-C_8) -alkoxy-, (C_1-C_8) -alkylcarbonyloxy- (C_1-C_4) -alkoxy- of and $R^{8'}$ where all residues R^8 and $R^{8'}$ are independent of one another and can be identical or different;

n is zero, one, two, three, four or five;

m is zero, one, two, three, four or five;

i is zero or one;

q is zero, one or two;

r is zero, one or two;

s is zero, one, two or three;

t is zero, one, two, three, four, five, six, seven or eight;

p is zero, one or two, where all numbers p are independent of one another and can be identical or different;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their <u>non-toxic</u>, physiologically tolerable salts and their prodrugs.

Claim 3 (currently amended) A compound of the formula I as claimed in claims 1 and/or 2, in which claim 1 wherein G is a residue of the formula II

$$-(CR^1R^2)_n$$
-A- $(CR^1R^2)_m$ - $(CR^1$ -R³)_i- $(CR^1R^2)_q$ -R⁴ #

A is <u>selected from the group consisting of</u> a direct bond, -C(O)NR⁵-, -NR⁵C(O)-, -C(O)-, -NR⁵- or and (C₅-C₁₄)-arylene where in the arylene <u>residue</u>, one or two ring carbon atoms can be replaced by heteroatoms a heteroatom selected from the <u>series group</u> consisting of nitrogen, oxygen and sulfur;

B is selected from the group consisting of (C_1-C_6) -alkyl, chlorine, hydroxy, cyano, trifluoromethyl, (C_1-C_6) -alkoxy, (C_1-C_6) -alkylcarbonyl-, (C_1-C_6) -alkanoylamino-, (C_1-C_6) -alkylamino of and di((C_1-C_6) -alkyl)amino-, where all residues Bs are independent of one another and can be identical or different;

X is hydrogen;

Y is hydrogen;

Z is N;

R¹ and R² are <u>individually selected from the group consisting of</u> hydrogen, (C₁-C₄)-alkyl, R⁶S(O)₂NHR⁷ or <u>and</u> R⁶OC(O)NHR₇, where all residues R⁴ and R² are independent of one another and can be identical or different;

 R^3 is selected from the group consisting of hydrogen, (C₁-C₁₂)-alkyl, (C₂ to C₁₈)-alkenyl, (C₂-C₁₈)-

alkynyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₆)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₆)-alkyl-, R⁶R⁶N-R⁷, R⁶S(O)₂N(R⁵)R⁷, R⁶OC(O)N(R⁵)R⁷ or and R⁶C(O)N(R⁵)R⁷, where alkyl can be mono-unsaturated or poly-unsaturated and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by a member selected from the group consisting of R⁶, fluorine, chlorine, trifluoromethyl, R⁶C(O)R⁷ or and R⁶-O-R⁷;

 R^4 is $-C(O)R^8$;

 R^5 is hydrogen or (C_1-C_4) -alkyl, where all residues R_5 are independent of one another and can be identical or different;

 R^6 and R^6 are individually selected from the group consisting of hydrogen, (C_1-C_{12}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl or and (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of members selected from the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C_1-C_6) -alkyl, (C_1-C_6) -alkoxy-, (C_1-C_6) -alkylamino-, di- $((C_1-C_6)$ -alkyl)amino-, (C_5-C_{14}) -aryl and (C_5-C_{14}) -heteroaryl, and where all residues R^6 are independent of one another and can be identical or different;

 R^7 is (C_1-C_2) -alkanediyl or a direct bond, where all residues $R^7\underline{s}$ are independent of one another and can be identical or different;

 R^8 is hydroxy or (C_1-C_6) -alkoxy;

n is zero, one, two, three, four or five;
m is zero or one;
i is zero or one;
q is zero or one;
r is zero or one;
s is zero, one or two;
t is zero, one, two, three or four;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their <u>non-toxic</u> physiologically tolerable salts and their prodrugs.

Claim 4 (currently amended) A compound of the formula I as claimed in one or more of claims 1 to 3, in which claim 1 wherein G is a residue of the formula II

$$-(CR^{1}R^{2})_{n}-A-(CR^{1}R^{2})_{m}-(CR^{1}R^{3})_{i}-(CR^{1}R^{2})_{q}-R^{4}$$
 #

A is a direct bond;

B is (C₁-C₆)-alkyl or hydroxy, where all residues Bs are independent of one another and can be identical or different;

X is hydrogen;

Ŷ is hydrogen;

Z is N;

R¹ and R² are <u>individually selected from the group consisting of</u> hydrogen, (C₁-C₄)-alkyl, R⁶S(O)₂NHR⁷ or <u>and</u> R⁶OC(O)NHR⁷, where all residues R¹ and R² are independent of one another and can be identical or different;

 R^3 is selected from the group from the group consisting of hydrogen, (C_1-C_{12}) -alkyl, (C_2-C_{12}) -alkenyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_6) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_6) -alkyl-, (C_5-C_{14}) -heteroaryl, (C_5-C_{14}) -heteroaryl- (C_1-C_6) -alkyl-, (C_5-C_1) -alkyl-, (C_5-C_1) -alkyl-, (C_5-C_1) -alkyl-, (C_5-C_1) -heteroaryl-, (C_5-C_1) -heteroaryl- (C_1-C_6) -alkyl-, (C_5-C_1) -alky

 R^4 is $-C(O)R^8$;

 R^5 is hydrogen or (C_1-C_4) -alkyl;

 R^6 and R^6 are individually selected from the group consisting of hydrogen, (C_1-C_{12}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl or (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents at least one substituent selected from the series group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C_1-C_6) -alkyl, (C_1-C_6) -alkylamino, di $((C_1-C_6)$ -alkyl)amino-, (C_5-C_{14}) -aryl and (C_5-C_{14}) -

heteroaryl, and where all R⁶s and R⁶s are independent of one another and can be identical or different;

R⁷ is a direct bond;

 R^8 is hydroxy or (C_1-C_4) -alkoxy;

n is zero, one or two;

m is zero or one;

i is zero or one;

q is zero or one;

r is zero or one;

s is zero, one or two;

t is zero;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their <u>non-toxic</u>, physiologically tolerable salts and their prodrugs.

Claim 5 (currently amended) A compound of the formula I as claimed in one or more of claims 1 to 4, which is a claim 1 wherein G is a residue of the formula II

$$-(CR^{1}R^{2})_{n}-A-(CR^{1}R^{2})_{m}-(CR^{1}R^{3})_{i}-(CR^{1}R^{2})^{q}-R^{4}$$
 H

A is a direct bond;

X is hydrogen;

Y is hydrogen;

Z is N;

 R^1 and R^2 are hydrogen or (C₁-C₂)-alkyl, where all $R^1\underline{s}$ and $R^2\underline{s}$ are independent of one another and can be identical or different;


R³ is selected from the group consisting of R⁶R⁶'N-R⁷, R⁶S(O)₂N(R⁵)R⁷ or and R⁶C(O)N(R⁵)R⁷;

 R^4 is $-C(O)R^8$;

 R^5 is hydrogen or (C_1-C_2) -alkyl;

 R^6 and R^6 are individually selected from the group consisting of hydrogen, (C_1-C_{12}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl of and (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl-where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents at least one substituent selected from the series group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C_1-C_6) -alkyl, (C_1-C_6) -alkoxy, (C_1-C_6) -alkylamino-, di- $((C_1-C_6)$ -alkyl)amino-, (C_5-C_{14}) -aryl and (C_5-C_{14}) -heteroaryl, and where the R^6 s and R^6 's are independent of one another and can be identical or different;

R⁷ is a direct bond;



R₁ and R² are hydrogen;

 R^{3} is $R^{6}S(O)_{2}N(R^{5})R^{7}$ or $R^{6}OC(O)N(R^{5})R^{7}$;

 R^4 is $-C(O)R^8$;

R⁵ is hydrogen;

 R^6 is selected from the group consisting of (C_1-C_{12}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl, (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -heteroaryl of and (C_5-C_{14}) -heteroaryl- (C_1-C_8) -alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents at least one substituent selected from the series group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C_1-C_6) -alkyl, (C_1-C_6) -alkylamino, di- $((C_1-C_6)$ -alkyl)amino-, (C_5-C_{14}) -aryl and (C_5-C_{14}) -heteroaryl;

R⁷ is a direct bond;

 R^8 is hydroxy or (C_1-C_4) -alkoxy;

n is one;

m is zero;

i is one;

q is zero;

r is zero;

s is zero;

t is zero;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their non-toxic, physiologically tolerable salts and their prodrugs.

Claim 7 (currently amended) A process for the preparation of a compound as claimed in one or more of claims 1 to 6, of claim 1 comprising reacting a compound of the formula VI

V١

with a compound of the of formula VIIa or with a compound of the formula VIIb

wherein L^1 is a leaving group and B, G, X, Y, r, s and t are defined as in claims 1 to 6 claim 1 but wherein functional groups can also be present in the form of precursor groups or in protected form.

Claim 8 (currently amended) A pharmaceutical composition, comprising at least one an amount of a compound of the formula I as claimed in one or more of claims 1 to 6 and/or its physiologically tolerable salts and/or its prodrugs claim 1 sufficient to act as a vitronectin receptor antagonist and a pharmaceutically acceptable carrier.

Claims 9-10 (cancelled)